The health insurance sector's first "key monitoring list" Drug companies to return to "pharmaceutical origin" is imminent.

Following the health department's key monitoring system for auxiliary drug use, the health insurance department has also begun to implement a key monitoring system for large "money-consuming" households.
Recently, in accordance with the spirit of the Fujian Provincial Medical Security Bureau's Notice on Strengthening the Management of Key Health Insurance Monitoring Drugs (No. 24 of The Fujian Provincial Medical Insurance Bureau), the Fujian Provincial Drug And Equipment Joint Procurement Center and the Fujian Provincial Medical Security Fund Center jointly published the "First Batch of Health Insurance Key Monitoring Drugs List" and "First Batch of Health Insurance Focus drug List".
the first batch of medical insurance key monitoring drugs a total of 10 product rules, all injections, the first batch of medical insurance focused on a total of 44 drugs.
management of the list of two types of medicines, which in principle is adjusted semi-annually.
industry believes that pharmaceutical companies should as soon as possible to assess the current medical insurance sector management methods on their own products, timely adjustment of promotion strategy and marketing team structure, product management concepts and practices should be immediately updated to clinical value.
"Focus monitoring" reflects the "two different" It is understood that Fujian Province at the beginning of the year carried out a provincial volume procurement, key monitoring policy documents followed by the release of the winning bid results, followed by the "first batch of health insurance key monitoring drug list" and "the first batch of health insurance focus on drug list" formally determined.
this can be said to be the health care sector in the centralized procurement of drugs outside the trial of a new method of fee control, of great significance. Liu Mingrui, a senior industry expert at
, explained that the two lists issued by Fujian Province included some varieties that were not suitable for volume or not yet purchased with volume, which was another new attempt by the health care sector to reduce drug prices.
Into the two lists of 54 varieties are a large amount, high amount, not included in the collection, or collection price reduction is not obvious, such as the bright propylene relin this variety, the front foot in Fujian Province with the volume of procurement in the flow mark, the back foot into the key monitoring list.
, the Fujian Provincial Health Insurance Bureau's aim is to push the variety to further reduce prices.
, the two lists also reflect the focus of surveillance in recent years.
and consulting founder Liu Chunying said that the first list of antimicrobial drugs, anti-tumor drugs, anticoagulant drugs, proton pump inhibitors, are clinical drug abuse "heavy-hit areas";
compared with the past, this time the "focus monitoring" list reflects two different: one is the main body of the text, the other is the controlled object.
the release of the focus monitoring list is the health care sector, not the health sector, and the "focus monitoring directory" refined to the product name.
For these two differences, Liu Chun-yi analysis said: "In the 'three-doctor linkage', health insurance as the largest single buyer of medical services and pharmaceutical commodities, the most conditional as a new organizer group to break the existing pattern of pharmaceutical circulation."
I stressed many years ago, 30 years east of the river 30 years west of the river, the previous order of medical circulation 30 years has not changed greatly, the old pattern of interests are entangled, in which the health care committee, commerce and other departments on the root of 'can not get their own life', by health insurance to break the situation is an established policy.
" Liu Mingrui pointed out that the health insurance bureau-led refinement to the commodity name of the key monitoring list, quite a precise blow to the meaning.
because the health insurance bureau is more motivated to reduce drug prices, so for pharmaceutical companies, it means both "control" and "price reduction", is undoubtedly worse.
from a controlled perspective, the two lists break through previous targeted monitoring of specific products, such as complementary medications, but cover a wide range of drug categories.
Liu Mingrui said in this regard, Fujian Health Insurance Bureau focus on monitoring the purpose is not only "control", more important is "price reduction", so the product categories involved are not limited to auxiliary drugs, many such as antibiotics, digestive drugs, if the Health Insurance Bureau found that the price is unreasonable, it may be included in this list.
It is worth mentioning that the 10 drugs in the First List of Key Monitoring Drugs for Health Care are all injection forms, which, in Liu Mingrui's view, should be related to the progress of consistent evaluation of injections.
He said that there are still many large amounts of injections because of failure to assess the national procurement, in order to reduce the price of this part of the injection, the Health Insurance Bureau can use provincial volume procurement and Fujian this "key monitoring" model for price control.
injection is easy to measure ah! Focus monitoring of complementary medications has been in place for many years, but complementary medications are an ambiguous and controversial concept.
The 10 injectable products are clinically large quantities, easy to abuse drugs, such as I have repeatedly stressed the serious harm of proton pump inhibitors involved in two products, and the strong promotion of low-molecular heparin makes it in many cases unreasonable replacement of low-cost common heparin.
there are two other antimicrobial drugs and three tumor-assisted medications.
" Liu Chunying also said in this analysis.
he also stressed that it was worth noting and reflecting on the fact that Liang's list of priorities had appeared twice, and once in the list of priorities.
"Two Lists" semi-annual adjustment "Fujian Provincial Medical Security Bureau on strengthening the focus of medical insurance monitoring drug management notice" also requires that the key monitoring list of drugs, the monthly delivery amount of more than 5 million yuan, reduce the list price, and adjust the maximum sales limit and medical insurance payment standards accordingly, lower the list price no longer callback.
, Liu Mingrui said, some of the key monitoring list is Fujian Province sales TOP20 "regular customers", the history of large sales.
to ensure clinical demand, companies need to cut prices.
the hospital's point of view, end-sales limits will drive changes in clinical drug use habits, reduce dosing, or replace them with other varieties.
At present, medical insurance as a strong Party A, whether it is price reduction or limit, short-term can achieve the purpose of fee control, but it is recommended that the relevant departments to introduce more evaluation indicators of drug economics, fully consider the needs of clinical drug use, not for the "control fee" and "control fee."
Liu Chunying also added that, limited to the current technical conditions and team conditions, medical insurance for clinical rational drug use monitoring is difficult to be nuanced, so the total number of ranking "shot the head bird" is a realistic and feasible extensive management method.
This way has long been used by large-scale triple-A hospitals around the country for many years, pharmaceutical companies are also very familiar with this, so it may have limited role, medical institutions will certainly face some products of the drug will face a month before loose tight situation.
particularly noteworthy is that the vast majority of the 44 product codes on the two lists are multinational pharmaceutical companies.
, why are imported drugs being focused? Liu Mingrui said that because of its clinical drug habits, in the original market share is high, the price is also high, some varieties even after the national election, still by virtue of its brand influence, at a higher price to occupy a considerable market share.
, as a supplement to national and provincial harvesting, Fujian uses the "focus monitoring" approach to focus on such products.
addition, Liu Chunying pointed out that domestic substitution is the main theme, and Chinese doctors have been educated by multinational pharmaceutical companies for many years, the dedication is quite deep, without strong administrative intervention can not be resolved.
addition, the pharmaceutical market is undergoing dramatic changes, such as volume procurement promotion, medical insurance drug catalog and base drug catalog adjustment, Fujian's list of key monitoring (concern) must not be static.
The Notice of fujian Provincial Medical Security Bureau on strengthening the management of key monitoring drugs for medical insurance clearly states that for drugs included in the list of key concerns, if there is abnormal procurement use and the rectification is not effective, timely adjustment shall be incorporated into the list of key monitoring drugs.
medical insurance to monitor the list of drugs and focus on the list of drugs to implement dynamic management, in principle, every six months to adjust.
in Liu Mingrui's view, the implementation of dynamic management is very wise, focusing on varieties may be included in the key monitoring list, is a warning to these varieties, the need to control prices and dosing.
and the two lists specific dynamic management rules indicate that there is still the possibility of directory additions, which is equivalent to a wake-up call for the species that have not yet been included.
and has entered the list of varieties sales must be hit, the focus of monitoring varieties will be forced to reduce prices or reductions, focus on varieties currently need to control abnormal growth, gradually tightening, to prevent access to the key monitoring list, the list of enterprises need to do a good job of early warning, the core focus is how to ensure "reasonable use", there are two paths: price reduction control and enhance clinical value.
Pharmaceutical companies should return to the source of pharmaceutical products on the Fujian health insurance sector issued two lists will have a far-reaching impact, Liu Chunying said, list management is a relatively rough management method, but simple and clear and have an explicit role in the performance, the current stage will still be the provincial and municipal health insurance departments and large public hospitals widely adopted.
pharmaceutical companies should clearly assess the impact of the current management style of the health insurance sector on their products, timely adjustment of promotion strategy and marketing team structure.
now, a considerable part of the market share of many large single-product sales depends on promotion, the risk of that part of the sales should be particularly pre-judged and addressed.
and practice of enterprise product management should be updated to clinical value immediately.
In addition, from the variety point of view, after the key monitoring of chemical drugs, biological drugs, Chinese medicine injections, chronic diseases and other major diseases of Chinese medicine also began to enter the focus list, the management of Chinese medicine will be from the provincial medical insurance focus gradually implemented to the national collection.
Liu Mingrui analysis pointed out that Fujian Province's reform has always been more radical, such as the "three-ming model" so that many enterprises feel the power of policy.
this "focus monitoring" initiative, the savings in health care funds can indeed have some effect, so it is easy to be some health care funding in the provinces and cities to follow suit.
, however, individuals feel that this means of medical insurance fee control also need to be improved in the system and evaluation dimension, so as not to affect the demand for clinical drug use.
for pharmaceutical companies, the impact of The "two lists" of Fujian's health-care sector is obvious.
in the province before the high sales of varieties, will soon face the market tightening dilemma, and some gradually release the amount of drugs, excessive sales of the amount of business fear.
All in all, these years of medical reform will make the pharmaceutical industry a big wave of sand, either "eat the last supper", or return to the source of pharmaceutical, in innovative drugs, clinically necessary, excellent quality varieties to work hard.
drug companies should have a clear understanding: the first decade of lying down can make money era is gone.
.